Skip to main content
Journal cover image

Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.

Publication ,  Journal Article
Luo, N; Mentz, RJ; O'Brien, EC
Published in: JACC Heart Fail
September 2017

Duke Scholars

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

September 2017

Volume

5

Issue

9

Start / End Page

689

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Humans
  • Heart Failure
  • Drug Combinations
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Luo, N., Mentz, R. J., & O’Brien, E. C. (2017). Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. JACC Heart Fail, 5(9), 689. https://doi.org/10.1016/j.jchf.2017.07.002
Luo, Nancy, Robert J. Mentz, and Emily C. O’Brien. “Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.JACC Heart Fail 5, no. 9 (September 2017): 689. https://doi.org/10.1016/j.jchf.2017.07.002.
Luo, Nancy, et al. “Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types.JACC Heart Fail, vol. 5, no. 9, Sept. 2017, p. 689. Pubmed, doi:10.1016/j.jchf.2017.07.002.
Journal cover image

Published In

JACC Heart Fail

DOI

EISSN

2213-1787

Publication Date

September 2017

Volume

5

Issue

9

Start / End Page

689

Location

United States

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Humans
  • Heart Failure
  • Drug Combinations
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology